Trastuzumab-containing regimens for metastatic breast cancer

Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study

“…Consistently with our findings, which demonstrated that the most common trastuzumab-related AEs were not serious, further studies confirmed that long term use of trastuzumab therapy is safe and well tolerated (Yeo et al, 2015 ), although the risk of neutropenia could be increased (Tripathy et al, 2004 ) along with gastrointestinal AEs and asthenia (Balduzzi et al, 2014 ). In a pivotal phase III trial, the addition of trastuzumab to chemotherapy in women with HER2 overexpressing metastatic breast cancer was associated to the occurrence of serious AEs, which included cardiac dysfunction, asthenia, leukopenia, dyspnea, and infusion reaction (Leonardi et al, 2010 ).…”

Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study

“…Consistently with our findings, which demonstrated that the most common trastuzumab-related AEs were not serious, further studies confirmed that long term use of trastuzumab therapy is safe and well tolerated (Yeo et al, 2015 ), although the risk of neutropenia could be increased (Tripathy et al, 2004 ) along with gastrointestinal AEs and asthenia (Balduzzi et al, 2014 ). In a pivotal phase III trial, the addition of trastuzumab to chemotherapy in women with HER2 overexpressing metastatic breast cancer was associated to the occurrence of serious AEs, which included cardiac dysfunction, asthenia, leukopenia, dyspnea, and infusion reaction (Leonardi et al, 2010 ).…”

Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada

“…In this retrospective population-based study of HER2 + aBC, the incidence of cardiac events during or after trastuzumab-based therapy was 7.3%, ( n = 167) with heart failure representing the majority of these events (6.9%, n = 158). These findings are similar to the 3–7% reported in the literature ( 6 , 8 , 14 ), but lower than a Dutch study of 429 patients likely given the reported combined incidence of severe and non-severe cardiotoxicity based on LVEF parameters of 11.7% and 9.1% after 1 and 2 years of trastuzumab respectively ( 21 ); after 4 years of treatment, the cumulative incidence of severe cardiotoxicity (LVEF < 40%) was 3.1%.…”

Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China

“…In spite of most conclusions derived from small cohorts or even suffering challenges [14], it could facilitate further scientific research of endogenous heterogeneity among diverse races and ethnicities. HER2 overexpression, as an independent indicator for the prognosis of HER2-positive breast cancer, is proverbially associated with a higher existence of early recurrence and distant metastasis [4]. In this study, visceral metastasis was shown in more than half of patients, which was in accordance with the general traits of HER2-positive breast cancer.…”

Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study

“…Consistently with our findings, which demonstrated that the most common trastuzumab-related AEs were not serious, further studies confirmed that long term use of trastuzumab therapy is safe and well tolerated (Yeo et al, 2015 ), although the risk of neutropenia could be increased (Tripathy et al, 2004 ) along with gastrointestinal AEs and asthenia (Balduzzi et al, 2014 ). In a pivotal phase III trial, the addition of trastuzumab to chemotherapy in women with HER2 overexpressing metastatic breast cancer was associated to the occurrence of serious AEs, which included cardiac dysfunction, asthenia, leukopenia, dyspnea, and infusion reaction (Leonardi et al, 2010 ).…”

Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada

“…In this retrospective population-based study of HER2 + aBC, the incidence of cardiac events during or after trastuzumab-based therapy was 7.3%, ( n = 167) with heart failure representing the majority of these events (6.9%, n = 158). These findings are similar to the 3–7% reported in the literature ( 6 , 8 , 14 ), but lower than a Dutch study of 429 patients likely given the reported combined incidence of severe and non-severe cardiotoxicity based on LVEF parameters of 11.7% and 9.1% after 1 and 2 years of trastuzumab respectively ( 21 ); after 4 years of treatment, the cumulative incidence of severe cardiotoxicity (LVEF < 40%) was 3.1%.…”

Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China

“…In spite of most conclusions derived from small cohorts or even suffering challenges [14], it could facilitate further scientific research of endogenous heterogeneity among diverse races and ethnicities. HER2 overexpression, as an independent indicator for the prognosis of HER2-positive breast cancer, is proverbially associated with a higher existence of early recurrence and distant metastasis [4]. In this study, visceral metastasis was shown in more than half of patients, which was in accordance with the general traits of HER2-positive breast cancer.…”

Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study

“…Consistently with our findings, which demonstrated that the most common trastuzumab-related AEs were not serious, further studies confirmed that long term use of trastuzumab therapy is safe and well tolerated (Yeo et al, 2015 ), although the risk of neutropenia could be increased (Tripathy et al, 2004 ) along with gastrointestinal AEs and asthenia (Balduzzi et al, 2014 ). In a pivotal phase III trial, the addition of trastuzumab to chemotherapy in women with HER2 overexpressing metastatic breast cancer was associated to the occurrence of serious AEs, which included cardiac dysfunction, asthenia, leukopenia, dyspnea, and infusion reaction (Leonardi et al, 2010 ).…”

Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada

“…In this retrospective population-based study of HER2 + aBC, the incidence of cardiac events during or after trastuzumab-based therapy was 7.3%, ( n = 167) with heart failure representing the majority of these events (6.9%, n = 158). These findings are similar to the 3–7% reported in the literature ( 6 , 8 , 14 ), but lower than a Dutch study of 429 patients likely given the reported combined incidence of severe and non-severe cardiotoxicity based on LVEF parameters of 11.7% and 9.1% after 1 and 2 years of trastuzumab respectively ( 21 ); after 4 years of treatment, the cumulative incidence of severe cardiotoxicity (LVEF < 40%) was 3.1%.…”

Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China

“…In spite of most conclusions derived from small cohorts or even suffering challenges [14], it could facilitate further scientific research of endogenous heterogeneity among diverse races and ethnicities. HER2 overexpression, as an independent indicator for the prognosis of HER2-positive breast cancer, is proverbially associated with a higher existence of early recurrence and distant metastasis [4]. In this study, visceral metastasis was shown in more than half of patients, which was in accordance with the general traits of HER2-positive breast cancer.…”